Review





Similar Products

ll  (ATCC)
99
ATCC ll
Ll, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ll/product/ATCC
Average 99 stars, based on 1 article reviews
ll - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier

95
Hycult Biotech elisa
Elisa, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/elisa/product/Hycult Biotech
Average 95 stars, based on 1 article reviews
elisa - by Bioz Stars, 2026-03
95/100 stars
  Buy from Supplier

99
ATCC ll 2 cells
The loss of SRC-3 in Treg suppress lung cancer progression in mice: (A) Experimental design for the orthotopic injection of lung cancer cells (luciferase labeled <t>LL/2)</t> into lung of mouse, followed by tamoxifen treatment to induce SRC-3 KO Tregs. (B) In vivo imaging analysis of luciferase activity in lung cancer-bearing SRC-3 f/f ( n = 5) and SRC-3 f/f :Foxp3 ERT2Cre/Y ( n = 5) male mice treated with tamoxifen. The lung tumor luciferase signal was very weak before tamoxifen treatment. Therefore, the luciferase image was overexposed to determine whether lung cancer cells had established in the lung. (C) H&E staining of lung from #2 and #5 SRC-3 f/f :Foxp3 ERT2Cre/Y in panel B. (D) Quantification of luciferase activity in lung cancer-bearing SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y male mice from panel B. Each line represents a single mouse. (E) Tumor luciferase activity was measured across three independent experiments. The total number of mice used for the SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y groups was 10 and 10, respectively. Luciferase activity was recorded for each mouse at the conclusion of the experiment. (F) Survival curve of SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y male mice with lung cancer. (G) Representative H&E staining of lung cancers harvested 18 d after tamoxifen treatment in SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y mice. Arrowheads indicated the lung cancer mass. (H–J) Levels of CD4⁺ T cells (H), CD8⁺ T cells (I), and NK cells, identified by CD49b staining (J), were assessed in melanomas harvested 18 d after tamoxifen treatment in SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y mice using IHC and quantified with the QuPath software. Statistical significance was determined using an unpaired two-tailed Student’s t -test in GraphPad Prism.
Ll 2 Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ll 2 cells/product/ATCC
Average 99 stars, based on 1 article reviews
ll 2 cells - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier

99
ATCC llc cell line
The loss of SRC-3 in Treg suppress lung cancer progression in mice: (A) Experimental design for the orthotopic injection of lung cancer cells (luciferase labeled <t>LL/2)</t> into lung of mouse, followed by tamoxifen treatment to induce SRC-3 KO Tregs. (B) In vivo imaging analysis of luciferase activity in lung cancer-bearing SRC-3 f/f ( n = 5) and SRC-3 f/f :Foxp3 ERT2Cre/Y ( n = 5) male mice treated with tamoxifen. The lung tumor luciferase signal was very weak before tamoxifen treatment. Therefore, the luciferase image was overexposed to determine whether lung cancer cells had established in the lung. (C) H&E staining of lung from #2 and #5 SRC-3 f/f :Foxp3 ERT2Cre/Y in panel B. (D) Quantification of luciferase activity in lung cancer-bearing SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y male mice from panel B. Each line represents a single mouse. (E) Tumor luciferase activity was measured across three independent experiments. The total number of mice used for the SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y groups was 10 and 10, respectively. Luciferase activity was recorded for each mouse at the conclusion of the experiment. (F) Survival curve of SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y male mice with lung cancer. (G) Representative H&E staining of lung cancers harvested 18 d after tamoxifen treatment in SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y mice. Arrowheads indicated the lung cancer mass. (H–J) Levels of CD4⁺ T cells (H), CD8⁺ T cells (I), and NK cells, identified by CD49b staining (J), were assessed in melanomas harvested 18 d after tamoxifen treatment in SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y mice using IHC and quantified with the QuPath software. Statistical significance was determined using an unpaired two-tailed Student’s t -test in GraphPad Prism.
Llc Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/llc cell line/product/ATCC
Average 99 stars, based on 1 article reviews
llc cell line - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier

99
ATCC murine lewis lung carcinoma llc1 ll 2 cells
The loss of SRC-3 in Treg suppress lung cancer progression in mice: (A) Experimental design for the orthotopic injection of lung cancer cells (luciferase labeled <t>LL/2)</t> into lung of mouse, followed by tamoxifen treatment to induce SRC-3 KO Tregs. (B) In vivo imaging analysis of luciferase activity in lung cancer-bearing SRC-3 f/f ( n = 5) and SRC-3 f/f :Foxp3 ERT2Cre/Y ( n = 5) male mice treated with tamoxifen. The lung tumor luciferase signal was very weak before tamoxifen treatment. Therefore, the luciferase image was overexposed to determine whether lung cancer cells had established in the lung. (C) H&E staining of lung from #2 and #5 SRC-3 f/f :Foxp3 ERT2Cre/Y in panel B. (D) Quantification of luciferase activity in lung cancer-bearing SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y male mice from panel B. Each line represents a single mouse. (E) Tumor luciferase activity was measured across three independent experiments. The total number of mice used for the SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y groups was 10 and 10, respectively. Luciferase activity was recorded for each mouse at the conclusion of the experiment. (F) Survival curve of SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y male mice with lung cancer. (G) Representative H&E staining of lung cancers harvested 18 d after tamoxifen treatment in SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y mice. Arrowheads indicated the lung cancer mass. (H–J) Levels of CD4⁺ T cells (H), CD8⁺ T cells (I), and NK cells, identified by CD49b staining (J), were assessed in melanomas harvested 18 d after tamoxifen treatment in SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y mice using IHC and quantified with the QuPath software. Statistical significance was determined using an unpaired two-tailed Student’s t -test in GraphPad Prism.
Murine Lewis Lung Carcinoma Llc1 Ll 2 Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/murine lewis lung carcinoma llc1 ll 2 cells/product/ATCC
Average 99 stars, based on 1 article reviews
murine lewis lung carcinoma llc1 ll 2 cells - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier

99
ATCC murine lewis lung carcinoma llc cell line
The loss of SRC-3 in Treg suppress lung cancer progression in mice: (A) Experimental design for the orthotopic injection of lung cancer cells (luciferase labeled <t>LL/2)</t> into lung of mouse, followed by tamoxifen treatment to induce SRC-3 KO Tregs. (B) In vivo imaging analysis of luciferase activity in lung cancer-bearing SRC-3 f/f ( n = 5) and SRC-3 f/f :Foxp3 ERT2Cre/Y ( n = 5) male mice treated with tamoxifen. The lung tumor luciferase signal was very weak before tamoxifen treatment. Therefore, the luciferase image was overexposed to determine whether lung cancer cells had established in the lung. (C) H&E staining of lung from #2 and #5 SRC-3 f/f :Foxp3 ERT2Cre/Y in panel B. (D) Quantification of luciferase activity in lung cancer-bearing SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y male mice from panel B. Each line represents a single mouse. (E) Tumor luciferase activity was measured across three independent experiments. The total number of mice used for the SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y groups was 10 and 10, respectively. Luciferase activity was recorded for each mouse at the conclusion of the experiment. (F) Survival curve of SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y male mice with lung cancer. (G) Representative H&E staining of lung cancers harvested 18 d after tamoxifen treatment in SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y mice. Arrowheads indicated the lung cancer mass. (H–J) Levels of CD4⁺ T cells (H), CD8⁺ T cells (I), and NK cells, identified by CD49b staining (J), were assessed in melanomas harvested 18 d after tamoxifen treatment in SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y mice using IHC and quantified with the QuPath software. Statistical significance was determined using an unpaired two-tailed Student’s t -test in GraphPad Prism.
Murine Lewis Lung Carcinoma Llc Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/murine lewis lung carcinoma llc cell line/product/ATCC
Average 99 stars, based on 1 article reviews
murine lewis lung carcinoma llc cell line - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier

99
ATCC crl 2539 murine lewis lung carcinoma llc1 ll 2 cells atcc
The loss of SRC-3 in Treg suppress lung cancer progression in mice: (A) Experimental design for the orthotopic injection of lung cancer cells (luciferase labeled <t>LL/2)</t> into lung of mouse, followed by tamoxifen treatment to induce SRC-3 KO Tregs. (B) In vivo imaging analysis of luciferase activity in lung cancer-bearing SRC-3 f/f ( n = 5) and SRC-3 f/f :Foxp3 ERT2Cre/Y ( n = 5) male mice treated with tamoxifen. The lung tumor luciferase signal was very weak before tamoxifen treatment. Therefore, the luciferase image was overexposed to determine whether lung cancer cells had established in the lung. (C) H&E staining of lung from #2 and #5 SRC-3 f/f :Foxp3 ERT2Cre/Y in panel B. (D) Quantification of luciferase activity in lung cancer-bearing SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y male mice from panel B. Each line represents a single mouse. (E) Tumor luciferase activity was measured across three independent experiments. The total number of mice used for the SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y groups was 10 and 10, respectively. Luciferase activity was recorded for each mouse at the conclusion of the experiment. (F) Survival curve of SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y male mice with lung cancer. (G) Representative H&E staining of lung cancers harvested 18 d after tamoxifen treatment in SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y mice. Arrowheads indicated the lung cancer mass. (H–J) Levels of CD4⁺ T cells (H), CD8⁺ T cells (I), and NK cells, identified by CD49b staining (J), were assessed in melanomas harvested 18 d after tamoxifen treatment in SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y mice using IHC and quantified with the QuPath software. Statistical significance was determined using an unpaired two-tailed Student’s t -test in GraphPad Prism.
Crl 2539 Murine Lewis Lung Carcinoma Llc1 Ll 2 Cells Atcc, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/crl 2539 murine lewis lung carcinoma llc1 ll 2 cells atcc/product/ATCC
Average 99 stars, based on 1 article reviews
crl 2539 murine lewis lung carcinoma llc1 ll 2 cells atcc - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier

crl  (ATCC)
99
ATCC crl
The loss of SRC-3 in Treg suppress lung cancer progression in mice: (A) Experimental design for the orthotopic injection of lung cancer cells (luciferase labeled <t>LL/2)</t> into lung of mouse, followed by tamoxifen treatment to induce SRC-3 KO Tregs. (B) In vivo imaging analysis of luciferase activity in lung cancer-bearing SRC-3 f/f ( n = 5) and SRC-3 f/f :Foxp3 ERT2Cre/Y ( n = 5) male mice treated with tamoxifen. The lung tumor luciferase signal was very weak before tamoxifen treatment. Therefore, the luciferase image was overexposed to determine whether lung cancer cells had established in the lung. (C) H&E staining of lung from #2 and #5 SRC-3 f/f :Foxp3 ERT2Cre/Y in panel B. (D) Quantification of luciferase activity in lung cancer-bearing SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y male mice from panel B. Each line represents a single mouse. (E) Tumor luciferase activity was measured across three independent experiments. The total number of mice used for the SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y groups was 10 and 10, respectively. Luciferase activity was recorded for each mouse at the conclusion of the experiment. (F) Survival curve of SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y male mice with lung cancer. (G) Representative H&E staining of lung cancers harvested 18 d after tamoxifen treatment in SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y mice. Arrowheads indicated the lung cancer mass. (H–J) Levels of CD4⁺ T cells (H), CD8⁺ T cells (I), and NK cells, identified by CD49b staining (J), were assessed in melanomas harvested 18 d after tamoxifen treatment in SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y mice using IHC and quantified with the QuPath software. Statistical significance was determined using an unpaired two-tailed Student’s t -test in GraphPad Prism.
Crl, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/crl/product/ATCC
Average 99 stars, based on 1 article reviews
crl - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier

94
ATCC lewis lung carcinoma llc
The loss of SRC-3 in Treg suppress lung cancer progression in mice: (A) Experimental design for the orthotopic injection of lung cancer cells (luciferase labeled <t>LL/2)</t> into lung of mouse, followed by tamoxifen treatment to induce SRC-3 KO Tregs. (B) In vivo imaging analysis of luciferase activity in lung cancer-bearing SRC-3 f/f ( n = 5) and SRC-3 f/f :Foxp3 ERT2Cre/Y ( n = 5) male mice treated with tamoxifen. The lung tumor luciferase signal was very weak before tamoxifen treatment. Therefore, the luciferase image was overexposed to determine whether lung cancer cells had established in the lung. (C) H&E staining of lung from #2 and #5 SRC-3 f/f :Foxp3 ERT2Cre/Y in panel B. (D) Quantification of luciferase activity in lung cancer-bearing SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y male mice from panel B. Each line represents a single mouse. (E) Tumor luciferase activity was measured across three independent experiments. The total number of mice used for the SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y groups was 10 and 10, respectively. Luciferase activity was recorded for each mouse at the conclusion of the experiment. (F) Survival curve of SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y male mice with lung cancer. (G) Representative H&E staining of lung cancers harvested 18 d after tamoxifen treatment in SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y mice. Arrowheads indicated the lung cancer mass. (H–J) Levels of CD4⁺ T cells (H), CD8⁺ T cells (I), and NK cells, identified by CD49b staining (J), were assessed in melanomas harvested 18 d after tamoxifen treatment in SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y mice using IHC and quantified with the QuPath software. Statistical significance was determined using an unpaired two-tailed Student’s t -test in GraphPad Prism.
Lewis Lung Carcinoma Llc, supplied by ATCC, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/lewis lung carcinoma llc/product/ATCC
Average 94 stars, based on 1 article reviews
lewis lung carcinoma llc - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier

94
ATCC luciferase 2 luc2
The loss of SRC-3 in Treg suppress lung cancer progression in mice: (A) Experimental design for the orthotopic injection of lung cancer cells (luciferase labeled <t>LL/2)</t> into lung of mouse, followed by tamoxifen treatment to induce SRC-3 KO Tregs. (B) In vivo imaging analysis of luciferase activity in lung cancer-bearing SRC-3 f/f ( n = 5) and SRC-3 f/f :Foxp3 ERT2Cre/Y ( n = 5) male mice treated with tamoxifen. The lung tumor luciferase signal was very weak before tamoxifen treatment. Therefore, the luciferase image was overexposed to determine whether lung cancer cells had established in the lung. (C) H&E staining of lung from #2 and #5 SRC-3 f/f :Foxp3 ERT2Cre/Y in panel B. (D) Quantification of luciferase activity in lung cancer-bearing SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y male mice from panel B. Each line represents a single mouse. (E) Tumor luciferase activity was measured across three independent experiments. The total number of mice used for the SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y groups was 10 and 10, respectively. Luciferase activity was recorded for each mouse at the conclusion of the experiment. (F) Survival curve of SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y male mice with lung cancer. (G) Representative H&E staining of lung cancers harvested 18 d after tamoxifen treatment in SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y mice. Arrowheads indicated the lung cancer mass. (H–J) Levels of CD4⁺ T cells (H), CD8⁺ T cells (I), and NK cells, identified by CD49b staining (J), were assessed in melanomas harvested 18 d after tamoxifen treatment in SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y mice using IHC and quantified with the QuPath software. Statistical significance was determined using an unpaired two-tailed Student’s t -test in GraphPad Prism.
Luciferase 2 Luc2, supplied by ATCC, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/luciferase 2 luc2/product/ATCC
Average 94 stars, based on 1 article reviews
luciferase 2 luc2 - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier

Image Search Results


The loss of SRC-3 in Treg suppress lung cancer progression in mice: (A) Experimental design for the orthotopic injection of lung cancer cells (luciferase labeled LL/2) into lung of mouse, followed by tamoxifen treatment to induce SRC-3 KO Tregs. (B) In vivo imaging analysis of luciferase activity in lung cancer-bearing SRC-3 f/f ( n = 5) and SRC-3 f/f :Foxp3 ERT2Cre/Y ( n = 5) male mice treated with tamoxifen. The lung tumor luciferase signal was very weak before tamoxifen treatment. Therefore, the luciferase image was overexposed to determine whether lung cancer cells had established in the lung. (C) H&E staining of lung from #2 and #5 SRC-3 f/f :Foxp3 ERT2Cre/Y in panel B. (D) Quantification of luciferase activity in lung cancer-bearing SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y male mice from panel B. Each line represents a single mouse. (E) Tumor luciferase activity was measured across three independent experiments. The total number of mice used for the SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y groups was 10 and 10, respectively. Luciferase activity was recorded for each mouse at the conclusion of the experiment. (F) Survival curve of SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y male mice with lung cancer. (G) Representative H&E staining of lung cancers harvested 18 d after tamoxifen treatment in SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y mice. Arrowheads indicated the lung cancer mass. (H–J) Levels of CD4⁺ T cells (H), CD8⁺ T cells (I), and NK cells, identified by CD49b staining (J), were assessed in melanomas harvested 18 d after tamoxifen treatment in SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y mice using IHC and quantified with the QuPath software. Statistical significance was determined using an unpaired two-tailed Student’s t -test in GraphPad Prism.

Journal: Oncoimmunology

Article Title: Steroid receptor coactivator 3-deficient regulatory T cells eradicate multiple solid tumors in syngeneic mouse models

doi: 10.1080/2162402X.2026.2640261

Figure Lengend Snippet: The loss of SRC-3 in Treg suppress lung cancer progression in mice: (A) Experimental design for the orthotopic injection of lung cancer cells (luciferase labeled LL/2) into lung of mouse, followed by tamoxifen treatment to induce SRC-3 KO Tregs. (B) In vivo imaging analysis of luciferase activity in lung cancer-bearing SRC-3 f/f ( n = 5) and SRC-3 f/f :Foxp3 ERT2Cre/Y ( n = 5) male mice treated with tamoxifen. The lung tumor luciferase signal was very weak before tamoxifen treatment. Therefore, the luciferase image was overexposed to determine whether lung cancer cells had established in the lung. (C) H&E staining of lung from #2 and #5 SRC-3 f/f :Foxp3 ERT2Cre/Y in panel B. (D) Quantification of luciferase activity in lung cancer-bearing SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y male mice from panel B. Each line represents a single mouse. (E) Tumor luciferase activity was measured across three independent experiments. The total number of mice used for the SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y groups was 10 and 10, respectively. Luciferase activity was recorded for each mouse at the conclusion of the experiment. (F) Survival curve of SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y male mice with lung cancer. (G) Representative H&E staining of lung cancers harvested 18 d after tamoxifen treatment in SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y mice. Arrowheads indicated the lung cancer mass. (H–J) Levels of CD4⁺ T cells (H), CD8⁺ T cells (I), and NK cells, identified by CD49b staining (J), were assessed in melanomas harvested 18 d after tamoxifen treatment in SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y mice using IHC and quantified with the QuPath software. Statistical significance was determined using an unpaired two-tailed Student’s t -test in GraphPad Prism.

Article Snippet: CT-2A (MilliporeSigma, Catalog number: SCC194), B16F10 (American Type Culture Collection, Catalog number: CRL-6475), and LL/2 cells (American Type Culture Collection, Catalog number: CRL-1642) were used to generate syngeneic mouse models of glioblastoma, melanoma, and lung cancer, respectively.

Techniques: Injection, Luciferase, Labeling, In Vivo Imaging, Activity Assay, Staining, Software, Two Tailed Test